Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…Abstract Number: 561 • 2014 ACR/ARHP Annual Meeting
A Psychometric Analysis of Outcome Measures in Trials of Peripheral Spondyloarthritis
Background/Purpose: We assessed the discriminatory aspects of disease activity measures and response criteria between adalimumab (ADA) and placebo (PBO) in 2 studies of patients (pts)…Abstract Number: 2581 • 2014 ACR/ARHP Annual Meeting
Clinically Active Non-Radiographic Axial Spondyloarthritis Patients Who Initially Have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint
Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) and active disease may have objective evidence of inflammation, either as bone marrow edema (BME) on magnetic…Abstract Number: 567 • 2014 ACR/ARHP Annual Meeting
Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata® Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab
Background/Purpose: Anti-TNF agents namely adalimumab (ADA), etanercept (ETA) and infliximab (INF) are approved for the treatment of signs and symptoms of ankylosing spondylitis. Their efficacy…Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…Abstract Number: 558 • 2014 ACR/ARHP Annual Meeting
Therapeutic Response in Adalimumab-Treated Patients with Non-Radiographic Axial Spondyloarthritis Is Similar Regardless of Body Mass Index
Background/Purpose: C-reactive protein (CRP), an objective measure of active inflammation, has been associated with obesity, with both overweight and obese individuals more likely to have…Abstract Number: 2510 • 2014 ACR/ARHP Annual Meeting
Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: To achieve comprehensive disease control (CDC; defined as simultaneous achievement of DAS28 < 3.2, HAQ-DI < 0.5 and ΔmTSS ≤ 0.5) or comprehensive disease…Abstract Number: 553 • 2014 ACR/ARHP Annual Meeting
Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Background/Purpose: To compare 1) extra-articular manifestations, 2) baseline comorbidities, and 3) adverse event (AE) rates with long-term adalimumab (ADA) therapy in patients (pts) treated in…Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…Abstract Number: 502 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab
Background/Purpose : Tocilizumab, as an intra-venous agent, has been approved for rheumatoid arthritis (RA) in Canada in April 30th, 2010. It was the sixth approved…Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting
Primary Human Cell BioMAP® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures
Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…Abstract Number: 1826 • 2013 ACR/ARHP Annual Meeting
Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …Abstract Number: 494 • 2013 ACR/ARHP Annual Meeting
Autoantibody Profiles Predict Responsiveness To Methotrexate and Anti-TNF Therapy In Early Rheumatoid Arthritis
Background/Purpose: Novel therapeutic concepts in early rheumatoid arthritis (ERA) are aiming for an early intervention and effective control of disease activity reaching remission. Most current…Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting
Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 17
- Next Page »